Homepage
Author:
Tenaya Therapeutics, Inc.
Posted Date:
May 6, 2026
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics, Inc.
May 6, 2026
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Tenaya Therapeutics, Inc.
April 27, 2026
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Tenaya Therapeutics, Inc.
March 11, 2026
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya Therapeutics, Inc.
March 9, 2026
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Tenaya Therapeutics, Inc.
March 5, 2026
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
Tenaya Therapeutics, Inc.
March 2, 2026
